Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 extension study of cendakimab in eosinophilic esophagitis
MOH_2022-01-06_010528Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cendakimab in eosinophilic esophagitis (EoE), sponsored by Celgene Corporation. Primary endpoint: Long-term safety and tolerability of cendakimab. Started Nov 2021; status: active, not recruiting.
02
Drugs
cendakimab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on MOH_2022-01-06_010528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-06_010528.